Delivery Order SPE2DB20D2104-SPE2DB24FV77P
Award Date
8/19/24
Potential Completion Date
8/20/24
Potential Value
$2.4K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $4,972.02 firm-fixed-price delivery order has a completion date of June 27, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $22,139.40, is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product. The contract type is a Delivery Order, with a Firm Fixed Price pricing structure, and an ultimate completion date of January 3, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,240.72 firm-fixed-price delivery order is for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml, a medication used in the treatment of cystic fibrosis. The contract has an ultimate completion date of November 14, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $9,411.56, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, Corporate Office Division. The contract is for the delivery of 4565902500 - PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product. It is a delivery order contract with a firm fixed price pricing type. The contract has an ultimate completion date of September 24, 2024. Amerisourcebergen, a major supplier of pharmaceutical products and medical...
This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a global pharmaceutical sourcing and distribution company. The contract is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, with a completion date of March 7, 2024. The potential value of the award is $12,070.46. Amerisourcebergen Drug Corp is the prime contractor and there is no...
This federal contract award is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $5,122.56 and was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of November 14, 2024. This award is not designated as a set-aside contract....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $8,428.28, is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication. The contract has a firm fixed-price pricing type and an ultimate completion date of August 21, 2024. This order is not designated as a set-aside contract. Amerisourcebergen Drug Corp, through its Corporate Office division, has been...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,543.24 firm fixed-price delivery order is for the provision of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medication used in the treatment of cystic fibrosis. The contract has an ultimate completion date of November 20, 2024.
Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award, SPE2DB22D1052|SPE2DB24FU9RP, is a Delivery Order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $27,879.81, is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a prescription medication. The award has a firm fixed price and an ultimate completion date of August 27, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award is for Delivery Order SPE2DB24FD5Z3 under Indefinite Delivery Contract SPE2DB20D1100, issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, Corporate Office Division. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, with a ceiling value of $53,831.06 and a performance period ending on September 4, 2024. The contract is a Firm Fixed Price type, with no set-aside designation....